PRO-CTCAE Task 8 Committee: Feasibility Research March 18 th 2011 (11am EST) Kickoff Telecon.

Slides:

Advertisements

Similar presentations

Background This linked collaborative is intended to identify opportunities to exchange best practices, administrative and regulatory support models and.

Advertisements

Characteristics of research. Designed to derive generalisable new knowledge.

Donald T. Simeon Caribbean Health Research Council

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic)

PHASE 1 Facilitating discussion on treatment preferences and advance care planning in cancer patients using the vignette technique Funding: Department.

A feasibility study to explore patient, clinician and GP decision making of acute recurrent tonsillitis for NATTINA: The NAtional Trial of Tonsillectomy.

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Ethan Basch, M.D. Memorial Sloan-Kettering.

AHRQ Annual Conference Patient-Reported Outcomes for Adverse Event Monitoring in Clinical Research Ethan Basch, M.D., M.Sc. Memorial Sloan-Kettering Cancer.

EVIDENCE BASED HEALTH CARE and BEST PRACTICES at Northwestern Health Sciences University Gert Bronfort DC, PhD; Michele Maiers, DC, MPH; Roni Evans DC,

ART-RIM Workshop National Cancer institute Ethan Basch, MD, MSc Memorial Sloan-Kettering Cancer Center Patient-reported Outcomes (PROs) January 22, 2010.

Patient Reported Outcomes in Oncology Trials Virginia Kwitkowski Clinical Reviewer-- FDA Division of Drug Oncology Products Member OND Patient Reported.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

Pilot Study Design Issues

Phase III Study Comparing Gemcitabine plus Cetuximab versus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma Southwest.

CTEP Program Meeting Patient-Reported Outcomes (PROs) in Cancer Treatment Trials Ethan Basch, MD, MSc Memorial Sloan-Kettering Cancer Center PROs for Adverse.

NCI-sponsored treatment trials: CTCAE v4 790 individual items Standard Approach to AE Monitoring CATEGORYEXAMPLEDATA SOURCE LaboratoryNeutropeniaLaboratory.

First Safety Data from a Randomized Phase III (CIBOMA/ /GEICAM ) Trial Assessing Adjuvant Capecitabine Maintenance Therapy After Standard.

Capecitabine versus 5-fluorouracil-based (neo-)adjuvant chemo-radiotherapy for locally advanced rectal cancer: Long term results.

Mark Frohlich, MD, SVP and Chief Medical Officer September 25, 2008 Washington, DC 4 th Annual African American Prostate Cancer Disparity Summit.

Phase III Randomized, Placebo-Controlled, Double-Blind Study of Intravenous Calcium/Magnesium to Prevent Oxaliplatin- Induced Sensory Neurotoxicity, N08CB.

Patient-Reported Outcomes Measurement Information System (PROMIS): Opportunities in Health Services Research Steven Clauser, Ph.D. National Cancer Institute.

Clinical Trial Data Validation Using SAS PROC SQL Jie Liu BIOS 524 Project 2003, Fall.

Copyright © 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 18 Mixed Methods and Other Special Types of Research.

Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Amylou C. Dueck (Mayo Clinic)

1 October, 2005 Activities and Activity Director Guidance Training (F248) §483.15(f)(l), and (F249) §483.15(f)(2)

Copyright © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 12 Undertaking Research for Specific Purposes.

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

CTEP, NCI Adverse Event Reporting Programmatic & Workflow Processes Prepared by: Ann Setser May 24, 2010.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Amany M. Shebl Professor Of Medical-surgical Nursing Dean. Nursing Faculty, Mansoura University, Egypt.

PRO-CTCAE Face-To-Face Meeting #2 Advancing the Science of Adverse Symptom Monitoring in Cancer Treatment Trials Amy P. Abernethy, MD Task 6: Usability.

Alice Chen, MD, FACP Investigational Drug Branch, CTEP, DCTD National Cancer Institute CTCAE Version 4.

Overview of NCI Supported Fatigue Trials Ann O’Mara, PhD, RN, FAAN.

Measuring the Feasibility and Cost of PRO-CTCAE Implementation in Trials Presentation to NCI Stakeholders Based on work of the PRO-CTCAE Task 8 (Feasibility)

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

EAE Training EAE Reporting and Assessment Overview DAIDS Regional Training Event, Regulatory Compliance Center Kampala, Uganda, September 2009 DAIDS Regional.

# 3564 Neurotoxicity with FULV versus FLOX in patients with stage II and III carcinoma of the colon: Results of NSABP Protocol C-07 S Land 1,2, J Kopec.

CaBIG Population Sciences SIG Ethan Basch, MD, MSc Memorial Sloan-Kettering Cancer Center PRO-CTCAE A system for patient self-reporting of adverse symptoms.

Assessment and Management of Depression, Anxiety, and Alcohol Problems in Primary Care: The BHL Program VISN 4 MIRECC VA Philadelphia University of Pennsylvania.

Bortezomib (VELCADE), Rituximab, Cyclophosphamide, Dexamethasone (VRCD) combination therapy in front-line low-grade non-Hodgkin lymphoma (LG-NHL) is active.

Bringing the Patient Voice into Cancer Care and Research Ethan Basch, MD, MSc November 19, 2015.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

How to Start An Industry Sponsored Clinical Trial

Locatelli F et al. Proc ASH 2013;Abstract 4378.

Evaluation Plan Steven Clauser, PhD Chief, Outcomes Research Branch Applied Research Program Division of Cancer Control and Population Sciences NCCCP Launch.

Sandra A. Mitchell, PhD, CRNP Outcomes Research Branch, DCCPS

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

1 Adherence Measures and Prediction of Clinical Outcomes in the China Adherence for Life (AFL) Cohort March 18, 2008 Lora Sabin Center for International.

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma [HCC] and Of its treatment with sorafeNib) second interim analysis in.

No Conflicts of Interest Including the Patient Voice in Safety Reporting Ethan Basch, MD, MSc Health Outcomes Group Departments of Medicine and Epidemiology/Biostatistics.

Sandra A. Mitchell, PhD, CRNP Research Scientist and Program Director Outcomes Research Branch, Applied Research Program Improving.

R2 민준기 / 정재헌 교수님. Introduction Patients with resected high-risk locally advanced head and neck cancer –Expect favorable outcomes after concomitant radiochemotherapy(CCRT)

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

New Patient telephone follow up clinic. Introduction North Tees and Hartlepool NHS Foundation Trust treat patients across two sites. We currently administer.

1 RTOG 1115 Health Related Quality of Life and Comparative Effectiveness Deborah Watkins Bruner, RN, PhD, FAAN.

PRAGMATIC Study Designs: Elderly Cancer Trials

C3PR: An Introduction for Users A Tool Demonstration from caBIG™ Vijaya Chadaram Duke Cancer Center April 29, 2008.

Alessandra Gennari, MD PhD

Mitchell Hickman Head and Neck Specialist Radiographer

Gajria D et al. Proc SABCS 2010;Abstract P

The DEPression in Visual Impairment Trial:

Expedited Adverse Event Reporting Requirements

Antineoplastic Medications

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Clinical Trial Results with OROS® Hydromorphone

Experience Design and Designing for Experience

GACD Annual Scientific Meeting

Methods for Identifying Treatment-Emergent Symptomatic Adverse Events from the Patient Perspective with Application to the PRO-CTCAE Gina L. Mazza, Ethan.

Yoga treatment for chronic non-specific low back pain

Presentation transcript:

PRO-CTCAE Task 8 Committee: Feasibility Research March 18 th 2011 (11am EST) Kickoff Telecon

Agenda 1 – Introductions 2 – Overview of PRO-CTCAE Task 8/SOW* 3 – Research questions/goals 4 – Protocols: Eribulin* (CALGB) and Manuka Honey (RTOG) 5 – Timeline 6 – Next call: Friday, 4/1/2011

CTCAE Lexicon of about 800 items to characterize adverse events Standard in all cancer clinical trials

Adverse Reactions Table

Example: Mucositis CTCAE/MedDRA Term CTCAE Grade 1CTCAE Grade 2CTCAE Grade 3CTCAE Grade 4 Mucositis oral Asymptomatic or mild symptoms; intervention not indicated Moderate pain; not interfering with oral intake; modified diet indicated Severe pain; interfering with oral intake Life-threatening consequences; urgent intervention indicated

CTCAE “Symptom Items” About 10% of CTCAE items are symptoms Currently reported by clinical staff Abundant evidence that staff under-reports important adverse symptom events

PRO-CTCAE In 2008, NCI contracted to develop and evaluate a patient version of the CTCAE, called the PRO-CTCAE

Other “Tasks” 1.Survey of cancer research stakeholders 2.Items developed 3.Cultural literacy assured 4.Cognitive interviews 5.Software platform developed 6.Usability testing 7.Validation study 8.Feasibility assessment (that’s us!)

Example: Mucositis CTCAE/MedDRA Term CTCAE Grade 1CTCAE Grade 2CTCAE Grade 3CTCAE Grade 4 Mucositis oral Asymptomatic or mild symptoms; intervention not indicated Moderate pain; not interfering with oral intake; modified diet indicated Severe pain; interfering with oral intake Life-threatening consequences; urgent intervention indicated Two ItemsResponses What was the severity of your MOUTH OR THROAT SORES at their worst? None Mild Moderate Severe Very Severe How much did MOUTH OR THROAT SORES interfere with your usual activities? Not at all A little bit Somewhat Quite a bit Very much

Create Form Form Builder

Manage Schedule

Secondary conditional item Shaking Chills Shivering

Study Reports

Patient-Reported Outcomes Version of the CTCAE

Aim 2: Conduct Feasibility Study

2 Trials Identified CALGB: Eribulin phase III RTOG: Manuka Honey randomized phase II

Eribulin Trial

PRO-CTCAE Preliminary Design 11 symptoms (20 items) – Fatigue, nausea, vomiting, diarrhea, constipation, insomnia, sensory neuropathy, mucositis, pain, anorexia, alopecia Administered via IVRS weekly Subcontract with CALGB and Mayo Aims: – 1: Discern between treatment arms – 2: Assess feasibility

Feasibility Patient-level – willing and able to self-report – satisfaction Staff-level (CRAs, investigators) – Willing/able to register/train patients – consider this a valuable activity Group-level and Site-level – Feasibility of implementation – Cost of implementation – Efficiency How do we measure these?

Site-Level Feasibility: In the Concept Semi-structured interviews with study personnel at selected sites Explore the barriers and challenges to implementation Assess cost, technical issues, and administrative burden DISCUSSION: How do we do this?